Navigation Links
Sitagliptin, Under Investigation For Type 2 Diabetes

The number of people suffering from diabetes is already over 194 million worldwide and the number is expected to increase by 333 million by 2025. Type II diabetes is also known as non-insulin dependent diabetes // and is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to an elevated glucose. In contrast to Type I diabetes, there is always some endogenous insulin production, and many patients have normal or even elevated blood insulin levels. The disease usually occurs over the age of 40 and treatment involves diet, oral hypoglycemic drugs and exogenous insulin.

However, side effect profile of the given medication, route of administration or difficulties in sustaining glucose control pose serious concerns and necessitate more tolerable treatments that do not cause weight gain and produce less risk of hypoglycemia for patients with type 2 diabetes.

Clinical phase II studies involving Sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

Sitagliptin is expected to lower blood glucose levels by increasing the level of active incretin hormones which increase insulin from pancreatic beta-cells and decrease glucagon from pancreatic alpha cells in a glucose-dependent manner (when blood glucose is elevated and not when blood glucose is low). If approved, Sitagliptin would be a member of a new class of antihyperglycaemic agents called DPP-IV inhibitors, which inhibit the DPP-4 enzyme that normally inactivates the incretin gut hormones GLP-1 and GIP. The patients studied exhibited a safety and tolerability profile similar to placebo. In addition, patients taking Sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia. Patients treated with glipizide had an average weight gain of 1.1 kilogram relative to placebo. Adverse event reports of hypoglycaemia were observed in 4 percent of patients taking Sitagliptin, 17 percent of patients taking glipizide and 2 percent of patients taking placebo.

Results from the studies conducted to date are very promising and ongoing Phase III trials are expected to provide greater insight into the efficacy and tolerability profile of Sitagliptin over a longer period of time.


'"/>




Related medicine news :

1. Undertaking the obesity epidemic
2. Breast Cancer in Men Often Underestimated and Under-treated
3. Drug to Lower Cholesterol Underused
4. Understanding The Predictors Of Prostate Cancer
5. Understanding Restless Legs Syndrome
6. Understanding Lung Cancer Metastasis
7. Understanding The Link Between Hormone Replacement and Respiratory Disease
8. Understanding The Risks Of Hormone Therapy
9. Understanding The Link Between Metabolic Syndrome And Drinking Patterns
10. A Better Understanding Of The Brain Network
11. Understanding The Predictor’s Of Alzheimer’s Diseae
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
Breaking Medicine Technology: